Interaction Between Nalbuphine and Morphine in PCA
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00155233 |
Recruitment Status : Unknown
Verified June 2005 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : September 12, 2005
Last Update Posted : November 23, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
- Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist
- This study was designed to investigate the interaction between nalbuphine and morphine
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postoperative Pain | Drug: Nalbuphine and morphine | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients |
Study Start Date : | January 2005 |

- analgesic effect
- incidence of opioid-related side effects

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18-65 y/o
- Female patients of ASA physical status I to III
- Scheduled for elective abdominal hysterectomy, myomectomy, or excision of ovarian tumor
Exclusion Criteria:
- Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants)
- Intraoperative fentanyl use > 3 μg/kg
- Patients with definite diagnosis of esophageal reflux syndrome
- Use of sedatives, antiemetics, or antipruritics within 24 hours before operation
- Surgery > 4 hours or laparoscopy surgery

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00155233
Taiwan | |
National Taiwan University Hospital | Recruiting |
Taipei, Taiwan, 100 | |
Contact: Yu Chang Yeh, MD cooltony@ha.mc.ntu.edu.tw | |
Principal Investigator: Wei-Zen Sun, MD |
Principal Investigator: | Wei-Zen Sun, MD | National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00155233 |
Other Study ID Numbers: |
931002 |
First Posted: | September 12, 2005 Key Record Dates |
Last Update Posted: | November 23, 2005 |
Last Verified: | June 2005 |
analgeisa postoperatve side effects |
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Morphine Nalbuphine |
Analgesics, Opioid Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents |